Quarterly report pursuant to Section 13 or 15(d)

Restatement of Previously Issued Financial Statements (Details) - Schedule of statement of changes in stockholders??? equity (Deficit)

v3.22.1
Restatement of Previously Issued Financial Statements (Details) - Schedule of statement of changes in stockholders’ equity (Deficit)
 9 Months Ended
Sep. 30, 2021
USD ($)
As Previously Reported [Member]  
Restatement of Previously Issued Financial Statements (Details) - Schedule of statement of changes in stockholders’ equity (Deficit) [Line Items]  
Net proceeds from Initial Public Offering allocated to Rights, net of transaction costs
Excess cash received over fair value of Private Placement Warrants 1,076,250
Change in fair value of over-allotment option liability
Accretion of common stock to possible redemption amount (15,993,222)
Net income (loss) 3,341,073
Adjustments [Member]  
Restatement of Previously Issued Financial Statements (Details) - Schedule of statement of changes in stockholders’ equity (Deficit) [Line Items]  
Net proceeds from Initial Public Offering allocated to Rights, net of transaction costs 3,845,969
Excess cash received over fair value of Private Placement Warrants 3,085,250
Change in fair value of over-allotment option liability 225,000
Accretion of common stock to possible redemption amount 623,508
Net income (loss) (7,779,727)
As Revised [Member]  
Restatement of Previously Issued Financial Statements (Details) - Schedule of statement of changes in stockholders’ equity (Deficit) [Line Items]  
Net proceeds from Initial Public Offering allocated to Rights, net of transaction costs 3,845,969
Excess cash received over fair value of Private Placement Warrants 4,161,500
Change in fair value of over-allotment option liability 225,000
Accretion of common stock to possible redemption amount (15,369,714)
Net income (loss) $ (4,438,654)